Navigation Links
Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
Date:6/16/2008

PRINCETON, N.J., June 16 /PRNewswire/ -- Celator Pharmaceuticals today announced that John Bennett, head of business development, is scheduled to present at the BIO Business Forum during the Biotechnology Industry Organization (BIO) International Convention in San Diego. Mr. Bennett will provide a corporate overview and an update on Celator's clinical development programs. The presentation will be held on Wednesday, June 18, 2008 at 3:30 PDT in Room 3 of the San Diego Convention Center.

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
4. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
5. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
6. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
9. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
10. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
11. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
(Date:10/9/2017)... N.C. (PRWEB) , ... October 09, 2017 , ... At ... announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, ... Stubbs was a member of the winning team for the 2015 Breakthrough Prize in ...
Breaking Biology Technology:
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):